These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35982681)

  • 21. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations.
    Jacobsen H; Strengert M; Maaß H; Ynga Durand MA; Katzmarzyk M; Kessel B; Harries M; Rand U; Abassi L; Kim Y; Lüddecke T; Metzdorf K; Hernandez P; Ortmann J; Heise JK; Castell S; Gornyk D; Glöckner S; Melhorn V; Kemmling Y; Lange B; Dulovic A; Marsall P; Häring J; Junker D; Schneiderhan-Marra N; Hoffmann M; Pöhlmann S; Krause G; Cicin-Sain L
    Sci Rep; 2022 Nov; 12(1):19858. PubMed ID: 36400804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
    Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.
    Li M; Beck EJ; Laeyendecker O; Eby Y; Tobian AAR; Caturegli P; Wouters C; Chiklis GR; Block W; McKie RO; Joyner MJ; Wiltshire TD; Dietz AB; Gniadek TJ; Shapiro AJ; Yarava A; Lane K; Hanley DF; Bloch EM; Shoham S; Cachay ER; Meisenberg BR; Huaman MA; Fukuta Y; Patel B; Heath SL; Levine AC; Paxton JH; Anjan S; Gerber JM; Gebo KA; Casadevall A; Pekosz A; Sullivan DJ
    Blood Adv; 2022 Jun; 6(12):3678-3683. PubMed ID: 35443020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
    Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.
    Richardson SI; Madzorera VS; Spencer H; Manamela NP; van der Mescht MA; Lambson BE; Oosthuysen B; Ayres F; Makhado Z; Moyo-Gwete T; Mzindle N; Motlou T; Strydom A; Mendes A; Tegally H; de Beer Z; Roma de Villiers T; Bodenstein A; van den Berg G; Venter M; de Oliviera T; Ueckermann V; Rossouw TM; Boswell MT; Moore PL
    Cell Host Microbe; 2022 Jun; 30(6):880-886.e4. PubMed ID: 35436444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant.
    Gallian P; Amroun A; Laperche S; Le Cam S; Brisbarre N; Malard L; Nurtop E; Isnard C; Richard P; Morel P; Tiberghien P; de Lamballerie X
    Vox Sang; 2022 Jul; 117(7):971-975. PubMed ID: 35577569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals.
    Park JS; Jeon J; Um J; Choi YY; Kim MK; Lee KS; Sung HK; Jang HC; Chin B; Kim CK; Oh MD; Lee CS
    Infect Chemother; 2024 Mar; 56(1):25-36. PubMed ID: 38014726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants.
    Planas D; Peng L; Zheng L; Guivel-Benhassine F; Staropoli I; Porrot F; Bruel T; Bhiman JN; Bonaparte M; Savarino S; de Bruyn G; Chicz RM; Moore PL; Schwartz O; Sridhar S
    Heliyon; 2024 Mar; 10(5):e27033. PubMed ID: 38486776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing antibody responses in vaccinated and unvaccinated individuals infected with Omicron BA.1 variant.
    Oh SJ; O SW; Choi YJ; Kim JM; Kim D; Kim IH; Park AK; Kim HM; Rhee JE; Jang YR; Yoo CK; Kim JY; Kim EJ
    J Clin Virol; 2022 Oct; 155():105253. PubMed ID: 35988369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2.
    Wang R; Zhang Q; Zhang R; Aw ZQ; Chen P; Wong YH; Hong J; Ju B; Shi X; Ding Q; Zhang Z; Chu JJH; Zhang L
    Front Immunol; 2022; 13():854952. PubMed ID: 35784344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
    Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.
    Branche AR; Rouphael NG; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Anderson EJ; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Malkin E; Bethony JM; Walsh EE; Graciaa DS; Samaha H; Sherman AC; Walsh SR; Abate G; Oikonomopoulou Z; El Sahly HM; Martin TCS; Rostad CA; Smith MJ; Ladner BG; Porterfield L; Dunstan M; Wald A; Davis T; Atmar RL; Mulligan MJ; Lyke KE; Posavad CM; Meagher MA; Stephens DS; Neuzil KM; Abebe K; Hill H; Albert J; Lewis TC; Giebeig LA; Eaton A; Netzl A; Wilks SH; Türeli S; Makhene M; Crandon S; Lee M; Nayak SU; Montefiori DC; Makowski M; Smith DJ; Roberts PC; Beigel JH;
    medRxiv; 2022 Jul; ():. PubMed ID: 35898343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients.
    Fu J; Shen X; Anderson M; Stec M; Petratos T; Cloherty G; Montefiori DC; Landay A; Moy JN
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
    Körper S; Jahrsdörfer B; Corman VM; Pilch J; Wuchter P; Blasczyk R; Müller R; Tonn T; Bakchoul T; Schäfer R; Juhl D; Schwarz T; Gödecke N; Burkhardt T; Schmidt M; Appl T; Eichler H; Klüter H; Drosten C; Seifried E; Schrezenmeier H
    Transfus Med Hemother; 2021 May; 48(3):137-147. PubMed ID: 34177417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.